Oppenheimer Maintains Buy Ratings For CBAY Price Target $19

Oppenheimer Maintains a Buy Rating on CymaBay Therapeutics (CBAY) https://www.analystratings.com/articles/oppenheimer-maintains-a-buy-rating-on-cymabay-therapeutics-cbay/

Oppenheimer has a price target for CBAY at $19. Not so fast. The price chart is displaying it will not make it that high. The price chart is showing a price target of $10 - $12, maybe $14.